Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Catfish who wrote (2487)	8/10/2001 11:13:32 AM
From: GARY P GROBBEL	Respond to of 120411

in listening to htis guy from Geron and others they are referrring at times to 'immortalized cells'. now, VODG may or may not be successful going forward but they are the only mini cap i can find that is actually working on an immortalized cell line...see this overview...do your own dd..trades otc bb with all the precautions that involves...around .50: VODG: COMPANY OVERVIEW The Company is presently focused on the development of proprietary, Naturally Pure Therapeutics through its discovery research team. We have a pipeline of products to treat human infertility and research program to develop a new platform technology with several applications including treatment of Alzheimer’s disease, diabetes and other degenerative disorders. The Company is building a substantial patent portfolio with one US patent issued and five other pending patent applications. Our first therapeutic target is the treatment of human infertility, where we plan the production of a series of improved products. Infertility is a major global health problem with 1 in 6 couples having problems in conception. The world’s market for fertility drugs is approaching $1 billion annually. Gonadotropins are the most widely used product to restore fertility. Our first product is VITROPIN ™ , which is urofollitropin for injection. VITROPIN ™ is a highly purified urinary FSH preparation produced according to the Company’s patented purification process. We believe that VITROPIN ™ has competitive advantages, including higher purity and cost-efficient production. VITROPIN ™ has been through an initial evaluation by the FDA. When the FDA approves of our development plan, we will commence clinical trials and seek approval of VITROPIN ™ as a new drug. The Company has exciting opportunities to capitalize upon its proprietary technologies. The realization of revenue potential of our technology requires leadership, scientific talent and capitalization of business development activities. We have initiatives underway to create alliances with compatible partners to assist in the commercialization of our products. Through such partnerships, we expect financial support and synergy that will fuel commercialization of the Company’s technology. We are also encouraged by the current government grant support of our research provided by the NIH. We intend to pursue additional opportunities for research grant support for the development of our technology. FERTILITY PRODUCT PIPELINE The Company is also developing additional products to treat infertility including VITROPIN- V ™ , VITROPIN-C ™ and VITROJECT ™ . VITROPIN-V ™ will be follitropin derived from VITROCELL-X ™ CELL IMMORTALIZATION TECHNOLOGY, which uses controlled over-expression of specific genes to produce cellular immortalization VITROPIN-V ™ will be the only product on the market identical to the body’s natural follitropins and will compete with premium-priced recombinant forms of FSH. VITROPIN-V ™ is expected to diminish the likelihood of side effects of current therapies, since the structure and pharmacology of this product are identical to FSH produced by the body. VITROPIN-C ™ will be a series of FSH products customized to specific patient needs, reducing the likelihood of complications of existing products such as multiple births. Vitro’s technology may result in new and innovative FSH drugs to lead the treatment of infertility in the 21st century. VITROPIN-C ™ may reduce ovarian hyper-stimulation, a rare but serious side effect of current fertility drugs. Vitro’s new invention may also reduce the requirement for daily injections of fertility drugs, which is presently needed for one to two weeks to be effective. VITROJECT ™ is a patent-pending syringe for cost-effective and efficient injection of drugs, including follitropins. Follitropin is now administered by daily mixing of a single dose, loading into a syringe and injection. This process is repeated daily for several days to achieve sufficient egg development to induce ovulation. VITROJECT ™ combines within a single device the mixing of an entire treatment regiment that can then be administered by repeated injection throughout the treatment period. CELLULAR IMMORTALIZATION TECHNOLOGY VITROCELL-X ™ is the designation of a series of immortalized cell lines. For example, VITROCELL-PG ™ is a cell line derived from the human pituitary cells that normally produce FSH. Since the FSH is derived from the cells of the body that normally produce it, this FSH is a Naturally Pure Therapeutic? identical to the FSH produced by the human body. VITROCELL-X ™ cell lines are produced by the Company’s proprietary platform technology method, which uses the controlled over-expression of specific genes to immortalize cells. The Company’s cell immortalization research is presently supported by a Small Business Innovation Research grant from the National Institute of Health (NIH). Most cells of the body will live only for a short time when removed from the body. Cells immortalized by Vitro’s method will continue to divide indefinitely. These cells maintain the normal cellular properties of fully differentiated cells, which allows for several significant medical uses of these cells. In addition to the products produced by VITROCELL-X CELL IMMORTALIZATION TECHNOLOGY ™ , the cell lines themselves represent commercial opportunities in: a) drug discovery, b) cell transplantation, and c) generation of artificial organs. Cell therapeutic approaches may also be applied to development of new treatments for Type I diabetes, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and spinal cord injury. Revised on July 26, 2001